Considerable scientific evidence confirms that interleukin (IL)-33 and its main receptor, suppression of tumorigenicity 2 (ST2), form a functional axis to modulate the development of esophageal inflammatory disorders, such as eosinophilic esophagitis and gastroesophageal reflux disease. Here, IL33 is linked to gastroesophageal reflux disease.